SEC Form 4 · accession 0001607062-16-000653
GENEREX BIOTECHNOLOGY CORP · GNBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Fletcher
Officer — President & CEO · Director
Period of report
Feb 9, 2016
Accepted (ET)
Feb 12, 2016 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001059784
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2016 | M | 14,890,033 | $0.001 | A | 10,442,992 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Purchase Option | $0.001 | Feb 9, 2016 | M | 1,457,195 | D | Jun 19, 2012 | Jun 19, 2017 | Common Stock | 1,457,195 | 0 | D |
| Common Stock Purchase Option | $0.001 | Feb 9, 2016 | M | 5,143,787 | D | Apr 1, 2013 | Apr 1, 2018 | Common Stock | 5,143,787 | 0 | D |
| Common Stock Purchase Option | $0.001 | Feb 9, 2016 | M | 1,587,300 | D | Jun 6, 2013 | Jun 6, 2018 | Common Stock | 1,587,300 | 0 | D |
| Common Stock Purchase Option | $0.001 | Feb 9, 2016 | M | 4,447,111 | A | Feb 9, 2016 | Oct 26, 2020 | Common Stock | 4,447,111 | 4,447,111 | D |